{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:11:36Z","timestamp":1776273096075,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1423,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1998,2]]},"abstract":"<jats:p>In patients with multiple myeloma, despite a major reduction of bone pain achieved with chemotherapy, skeletal disease continues to progress. The effects of clodronate, an inhibitor of osteoclastic bone resorption, are evaluated on the natural history of skeletal disease in patients with newly diagnosed multiple myeloma. Within the framework of the VIth MRC Multiple Myeloma Trial, 536 patients (218 women, 318 men) with recently diagnosed multiple myeloma were randomized to receive either clodronate 1600\u2003mg daily (<jats:italic>n<\/jats:italic>=264) or an outwardly identical placebo (<jats:italic>n<\/jats:italic>=272) in addition to chemotherapy. Treatment with clodronate was associated with a 50% decrease in the proportion of patients with severe hypercalcaemia (5.1% <jats:italic>v<\/jats:italic> 10.1%, <jats:italic>P<\/jats:italic>=0.06) and a similar reduction in reported non\u2010vertebral fractures (6.8% <jats:italic>v<\/jats:italic> 13.2%, <jats:italic>P<\/jats:italic>=0.04). Fewer patients receiving clodronate sustained vertebral fractures after entry to the trial (38% <jats:italic>v<\/jats:italic> 55%, <jats:italic>P<\/jats:italic>=0.01) and patients also lost less height over 3 years compared to those receiving placebo (2.0 <jats:italic>v<\/jats:italic> 3.4 cm, <jats:italic>P<\/jats:italic>=0.01). Biochemical indices of bone turnover were significantly lower in patients receiving concomitant clodronate, both at plateau and at disease relapse. The frequencies of back pain and poor performance status were significantly lower at 24 months in clodronate than in placebo\u2010treated patients (10.9% <jats:italic>v<\/jats:italic> 19.9%, <jats:italic>P<\/jats:italic>=0.05, and 18.3% <jats:italic>v<\/jats:italic> 30.5% <jats:italic>P<\/jats:italic>=0.03 respectively.) There was no statistically significant difference in survival between the clodronate and placebo treated patients. The study indicates that long\u2010term oral clodronate slows the progression of skeletal disease in multiple myeloma and decreases the associated morbidity. Patients without overt skeletal disease at diagnosis were also found to benefit from clodronate, indicating that this treatment should be initiated as early in the course of the disease as possible.<\/jats:p>","DOI":"10.1046\/j.1365-2141.1998.00567.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T05:58:42Z","timestamp":1047362322000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":252,"title":["A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma"],"prefix":"10.1111","volume":"100","author":[{"family":"McCloskey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Drayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Kanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the MRC Working Party on Leukaemia in Adults","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-83668-8_6"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000225610"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114392"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1397"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_7_7_2","first-page":"787","article-title":"Interleukin\u20106 causes hypercalcaemia in vivo, and enhances the bone resorbing potency of interleukin\u20101 and tumor necrosis factor by two orders of magnitude in vitro","volume":"5","author":"Black K.","year":"1990","journal-title":"Journal of Bone Mineralization"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92272-4"},{"key":"e_1_2_7_9_2","unstructured":"Dixon W. Brown M. Engleman L.(1985)BMDP Statistical Software Manual 5th edn. University of California Press Berkeley."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92755-1"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90101-M"},{"key":"e_1_2_7_12_2","unstructured":"Fleisch H.(1995)Bisphosphonates in Bone Disease: from the Laboratory to the Patient 2nd edn. The Parthenon Publishing Group London."},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2106\/00004623-198466040-00016","article-title":"Effects of chemotherapeutic agents on bone. I. Short\u2010term methotrexate and doxorubicin (adriamycin) treatment in a rat model","volume":"66","author":"Freidlander G.E.","year":"1984","journal-title":"Journal of Bone and Joint Surgery"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198708273170902"},{"key":"e_1_2_7_15_2","unstructured":"Kanis J.A.&McCloskey E.V.(1990) The use of clodronate in disorders of calcium and skeletal metabolism.Calcium Metabolism: Programme Basic Clinical Pharmacology(ed. by J. A. Kanis) pp.89136. Karger Basel."},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(96)00285-2"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863"},{"key":"e_1_2_7_19_2","first-page":"29","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle R.A.","year":"1975","journal-title":"Mayo Clinic Proceedings"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93075-X"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90004-M"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623275"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90739-0"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(91)90057-P"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.102"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.59"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_7_28_2","first-page":"833","article-title":"A prospective, controlled, non\u2010randomised study on prophylactic parenteral dicholoromethylene bisphosphonate (clodronate) in multiple myeloma","volume":"5","author":"Riccardi A.","year":"1994","journal-title":"International Journal of Oncology"},{"key":"e_1_2_7_29_2","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki A.","year":"1995","journal-title":"Cancer Research"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00046.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb03936.x"},{"key":"e_1_2_7_32_2","unstructured":"Warburton P. Dunn J.A. Maclennan I.C.M.(1994)Cambridge Medical Reviews: Haematological Oncology Vol. 3 pp.95114. Cambridge University Press."},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb01823.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.1998.00567.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.1998.00567.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.1998.00567.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:06:21Z","timestamp":1697443581000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.1998.00567.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,2]]}},"alternative-id":["10.1046\/j.1365-2141.1998.00567.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00567.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,2]]},"assertion":[{"value":"2001-12-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}